证券代码：002603 证券简称：以岭药业 公告编号：2025-007 石家庄以岭药业股份有限公司 关于收到化学原料药上市申请批准通知书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没 有虚假记载、误导性陈述或重大遗漏。 近日，石家庄以岭药业股份有限公司（以下简称"公司"）全资孙公司万洋 衡水制药有限公司（以下简称"衡水万洋"）收到国家药品监督管理局下发的《化 学原料药上市申请批准通知书》，由衡水万洋提交的"来曲唑"化学原料药上市 申请已获批准。现就相关事项公告如下： 截止目前，公司来曲唑原料药累计研发投入约 470 万元，涵盖工艺开发、质 量研究、稳定性研究及注册申报等环节。 申请事项：境内生产化学原料药上市申请 一、批准通知书基本内容 化学原料药名称：来曲唑 登记号：Y20230001258 生产企业名称：万洋衡水制药有限公司 主要结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册。质量标准、生产工艺及标签照所附执行。 二、药品的基本情况 化学原料药英文名/拉丁名：Letrozole 来曲唑（Letrozole）是一种高效、选择性非甾体类芳 ...

Group 1 - The company Yiling Pharmaceutical (002603) announced that its wholly-owned subsidiary, Wanyang Hengshui Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the listing application of the chemical raw material drug Letrozole [1] - Letrozole is a highly effective, selective non-steroidal aromatase inhibitor used in the treatment of breast cancer [1] - The global breast cancer drug market is expected to reach USD 37.6 billion by 2025 and between USD 45 billion to USD 55 billion by 2030 [1] Group 2 - The incidence of breast cancer in China is rising annually, leading to an expected continuous growth in the demand for raw materials [1] - The company has invested approximately CNY 4.7 million in the research and development of Letrozole raw materials [1] - The approval enriches the company's product line and helps to expand its business scope, although it is not expected to have a significant impact on performance at this time [1]

石家庄以岭药业股份有限公司 关于提前归还部分补充流动资金的募集资金的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：002603 证券简称：以岭药业 公告编号：2025-006 石家庄以岭药业股份有限公司（以下简称"公司"）于 2024 年 7 月 8 日分别 召开第八届董事会第十二次会议和第八届监事会第七次会议，审议通过了《关于 使用部分闲置非公开发行募集资金暂时补充流动资金的议案》，决定使用 2017 年 非公开发行募集资金项目部分闲置资金不超过人民币 39,000 万元暂时补充流动 资金，使用期限为自董事会批准之日起不超过 12 个月。相关公告详见刊登于 2023 年 7 月 8 日《中国证券报》《上海证券报》《证券时报》《证券日报》和巨潮资讯 网(www.cninfo.com.cn) 的《关于使用部分闲置非公开发行募集资金暂时补充流 动资金的公告》（公告编号 2024-024）。 2025 年 4 月 24 日，公司将上述用于暂时补充流动资金的募集资金人民币 22,000 万元提前归还至对应募集资金专户。剩余未归还的暂时补充流动资金的募 ...

胡润研究院于4月16日正式发布《2024胡润品牌榜》，评选出中国300强最具价值品牌。其中，以岭药业（002603）凭借其卓越的品牌影响力和市场表现，成 功跻身"地区最具价值品牌前三名"，并荣登医疗健康品牌价值TOP10，再次彰显了其在医药健康行业的领军地位。 作为中国品牌价值100强企业，以岭药业始终坚持"市场龙头，科技驱动"的创新发展战略，构建了"理论-临床-科研-产业-教学"五位一体的运营模式，形成了 涵盖专利中药、化生药、健康产业三大业务板块的产业格局。以岭药业在科技创新领域的成就尤为突出，荣获6项国家科技大奖，其中"中医脉络学说构建及 其指导微血管病变防治"荣获2019年度国家科技进步一等奖，这是年度生命科学领域唯一一项一等奖。 近两年，国家重点研发计划"脉络学说营卫理论指导系统干预心血管事件链研究"取得重大突破，相关成果入选2024世界传统医药大会标志性案例，并获中国 中西医结合学会科学技术一等奖。尤其值得一提的是，该项目子课题通心络胶囊治疗急性心梗相关研究成果登上《美国医学会杂志》(JAMA)，成为中医药 国际化进程中的里程碑事件。此外，连花清瘟胶囊、通心络胶囊等专利产品不仅在国内市场广受认可， ...

Core Insights - The Wuzhen Health Conference held from April 8 to 12 showcased the achievements of Yiling Pharmaceutical in digital transformation and innovation, earning multiple awards including "Top 10 Digital Model Enterprises in Pharmaceutical Manufacturing" and "Top 20 Digital Leading Enterprises in Pharmaceutical Retail" [1][2] Digital Transformation - Yiling Pharmaceutical has over 30 years of experience in traditional Chinese medicine, focusing on integrating digital technologies like big data and artificial intelligence to optimize drug development and accelerate innovation [2] - The company has established a comprehensive digital system covering research, production, and quality control, enhancing product quality and traceability through smart manufacturing and IoT technologies [2] - Yiling has built over 60 medicinal herb cultivation bases across seven major production areas in China, utilizing digital management systems to ensure standardized and sustainable raw material quality [2] Brand Strategy Innovation - Yiling Pharmaceutical emphasizes innovation in its brand strategy, aiming to create a globally influential traditional Chinese medicine brand [3] - The company has developed a series of innovative traditional Chinese medicines guided by the theory of meridian diseases, achieving significant recognition including six national science and technology awards [3] - Products like Tongxinluo capsules and Qiliqiangxin capsules have gained a strong reputation among consumers for treating cardiovascular diseases and other health issues [3] Product Positioning Innovation - Yiling Pharmaceutical focuses on accurately meeting diverse consumer health needs through innovative product positioning [4] - The company’s product, Wanbi'an Suanzaoren Oil Soft Capsules, won the "Soso Rabbit Health Goodies - Preferred Award" for its unique approach to sleep improvement [4] - Research indicates that Suanzaoren oil significantly enhances deep sleep quality and alleviates anxiety without dependency, making it popular among consumers [4] Market Channel Innovation - Yiling Pharmaceutical actively innovates in market channels, expanding beyond traditional sales methods to include online platforms and live-streaming sales [5] - The company promotes the internationalization of traditional Chinese medicine through evidence-based research, with products like Tongxinluo capsules registered in over 50 countries [5] - Yiling's market channel strategy focuses on comprehensive coverage, international breakthroughs, brand synergy, and digital empowerment, transitioning from a traditional pharmaceutical company to a modern, international health service provider [5]

Group 1 - The Fourth International Traditional Chinese Medicine Anti-Aging Conference was successfully held in Wuzhen, Zhejiang, gathering global experts to discuss advancements in anti-aging research and future prospects [1][3] - The release of the "Expert Consensus on Traditional Chinese Medicine Intervention in Aging" marks a significant step in establishing evidence-based practices for anti-aging treatments, particularly highlighting the role of Ba Zi Bu Shen capsules [3][8] Group 2 - Research indicates that aging can be treated as a disease, with 31.4% of 293 diseases identified as age-related, including major conditions like heart disease, stroke, and diabetes, which account for approximately 50% of mortality rates [4] - The Ba Zi Bu Shen capsule has shown effectiveness in improving aging symptoms, enhancing quality of life, and increasing physical capabilities in elderly populations through clinical studies conducted by multiple centers [5][6] Group 3 - Ba Zi Bu Shen capsules have become a significant product for Yiling Pharmaceutical, with sales showing a notable increase compared to the previous year, supported by effective marketing strategies and partnerships with retail pharmacies [6][8] - The aging population in China is projected to exceed 300 million by the end of 2024, representing 22% of the total population, indicating a vast market potential for anti-aging products [8]

Core Insights - The Fourth International Conference on Traditional Chinese Medicine Anti-Aging was held in Wuzhen, Zhejiang, focusing on the theme "Scientific Anti-Aging: Unlocking the Secrets to Health and Longevity" [1] - Yiling Pharmaceutical's Ba Zi Bu Shen capsules were highlighted as a representative innovative traditional Chinese medicine for anti-aging, receiving recognition for its effectiveness in anti-aging during the conference [1] Group 1: Scientific Foundations - Professor Jia Zhenhua emphasized that kidney essence deficiency is fundamental to aging, and maintaining kidney essence is key to anti-aging, supported by the Qi-Luo theory [3] - Ba Zi Bu Shen capsules have been shown to intervene in eight biological markers of aging, including reducing senescent cells and maintaining mitochondrial homeostasis [3] Group 2: Research and Development - A national key research project led by Professor Jia aims to explore the biological mechanisms of anti-aging in traditional Chinese medicine, focusing on various aging diseases and establishing a multi-level evaluation system [4] - A randomized double-blind clinical study published in 2024 demonstrated that Ba Zi Bu Shen capsules significantly improved aging symptoms related to energy, musculoskeletal health, and cognitive function, with a 76.7% increase in telomerase activity compared to the placebo group [5] Group 3: Global Perspectives - The conference featured discussions on the unique advantages of traditional Chinese medicine in addressing aging, with international experts highlighting the comprehensive protective effects of Ba Zi Bu Shen compared to single-target approaches like NMN [9] - The "Expert Consensus on Traditional Chinese Medicine Intervention in Aging" was released, further elaborating on the mechanisms of the Qi-Luo theory and Ba Zi Bu Shen capsules [12] Group 4: Demographic Context - By the end of 2024, the elderly population in China is expected to exceed 300 million, accounting for 22.0% of the total population, highlighting the importance of traditional Chinese medicine in addressing aging-related diseases [11] - The conference underscored the role of traditional Chinese medicine in promoting "healthy aging" through its unique philosophy of prevention and balance [11]

Group 1 - The core point of the announcement is that Shijiazhuang Yiling Pharmaceutical Co., Ltd. has received a formal acceptance notice from the National Medical Products Administration for the new drug registration application of "Qigui Luobitong Tablets" submitted by its wholly-owned subsidiary Beijing Yiling Pharmaceutical Co., Ltd. [1][3] Group 2 - "Qigui Luobitong Tablets" is an innovative traditional Chinese medicine classified as Category 1.1, designed to treat symptoms associated with rheumatoid arthritis, such as joint swelling, pain, and stiffness [2]. Group 3 - The acceptance of the drug registration application will lead to a series of evaluations and inspections by the National Medical Products Administration, but the uncertainty in completion time and approval results means that this development will not impact the company's short-term performance [3].

石家庄以岭药业股份有限公司 关于收到药品注册申请受理通知书的公告 证券代码：002603 证券简称：以岭药业 公告编号：2025-005 主要结论：根据《中华人民共和国行政许可法》第三十二条的规定，经审查， 决定予以受理。 二、药品的基本情况 芪桂络痹通片是公司自主研制的 1.1 类中药创新药，其功能主治为：祛风散 寒除湿，蠲痹通络止痛。用于类风湿关节炎风寒湿痹证，症见肢体关节肿胀、疼 痛、晨僵，关节压痛，关节屈伸不利、活动受限，关节疼痛游走不定、遇寒加重， 肢体重着，畏寒恶风，神疲乏力等。 三、对公司的影响及主要风险提示 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没 有虚假记载、误导性陈述或重大遗漏。 近日，石家庄以岭药业股份有限公司（以下简称"公司"）全资子公司北京 以岭药业有限公司（以下简称"北京以岭"）收到国家药品监督管理局下发的《受 理通知书》，由北京以岭提交的"芪桂络痹通片"新药注册申请已获正式受理。 现就相关事项公告如下： 一、受理通知书基本内容 申 请 人：北京以岭药业有限公司 申请事项：境内生产药品注册 产品名称：芪桂络痹通片 受 理 号：CXZS2500014 根据国家药品 ...

证券代码：002603 证券简称：以岭药业 公告编号：2025-004 2、股东股份累计被质押的情况 截至公告披露日，上述股东及其一致行动人所持质押股份情况如下： | | | | 本次补充 | 本次补充质 | 占其所 | 占公司 | 已质押股份 情况 | | 未质押股份 情况 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东 | 持股数量 | 持股比 | 质押前质 | 押后质押股 | | | | | | | | | | | | | 持股份 | 总股本 | | | | | | 名称 | （股） | 例 | 押股份数 | 份数量 | 比例 | 比例 | 已质押股份 | 占已质 | 未质押股份 | 占未质 | | | | | 量（股） | （股） | | | | | | | | | | | | | | | 限售和冻结 | 押股份 | 限售和冻结 | 押股份 | | | | | | | | | 数量（股） | 比例 | 数量（股） | 比例 | | 以岭 | | | | | | | | | | | | --- | ...